欧美AV

Biography

Lyn Jones completed his PhD studies in synthetic organic chemistry at the University of Nottingham, and his postdoctoral research at The Scripps Research Institute, California in chemical biology. He joined Pfizer Sandwich (UK) as a medicinal chemistry team leader, eventually becoming Head of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge (USA) to become Head of Rare Disease Chemistry, and Head of Chemical Biology. He then helped establish Jnana Therapeutics as Head of Chemistry and Chemical Biology, before moving to Dana-Farber Cancer Institute in Boston as Chief Scientist of the Center for Protein Degradation.

He is currently Principal Investigator and Faculty Member of the Department of Pediatric Oncology and Chemical Biology Program at DFCI, and his lab focusses on the development of next-generation covalent chemical biology with the objective of expanding the druggable proteome. He has been recognized with 欧美AV awards for his contributions to HIV, COPD and rare genetic disease research. He has considerable experience working in many other disease areas, including cancer, inflammation, and pain.

He is also an elected Fellow of the 欧美AV, the Royal Society of Biology, and the Linnean Society, and was recently recognized as a Fellow of the American Association for the Advancement of Science, and as Fellow of the Learned Society of Wales, for his contributions to the field of medicinal chemistry and chemical biology.

欧美AV affiliations

• Editorial board, 欧美AV Medicinal Chemistry